Blog
RSS FeedPosted by Michael Wonder on 05 Jul 2023
ICER to assess treatment for schizophrenia
5 July 2023 - Report will be subject of New England CEPAC meeting in February 2024; draft scoping document open ...
Posted by Michael Wonder on 04 Oct 2022
Newly approved ALS drug Relyvrio to face its next challenge: pricing and reimbursement
4 October 2022 - There’s a swirl of controversy surrounding last week’s regulatory approval of Relyvrio (sodium phenylbutyrate and taurursodiol), which ...
Posted by Michael Wonder on 23 Sep 2020
ICER issues final report and policy recommendations on treatments for cystic fibrosis
23 September 2020 - Independent appraisal committee unanimously concludes that Trikafta delivers substantial benefits for patients, family members, and society. ...
Posted by Michael Wonder on 04 May 2018
ICER finds that at current prices CFTR modulators for cystic fibrosis improve patient outcomes at costs that far exceed standard cost-effectiveness levels
3 May 2018 - Evidence report findings and contextual factors related to treatments for ultra-rare disorders such as cystic fibrosis ...
Posted by Michael Wonder on 01 Nov 2017
Institute for Clinical and Economic Review posts draft scoping document to guide review of tezacaftor and lumacaftor for cystic fibrosis
31 October 2017 - Document open to public comment until 20 November 2017. ...